|
Die Meldungen um das Medikament zur erhaltung der Sehkraft sind sehr gut und tragen zur allgemeinen Aufwertung der Aktie von Pfizer sicher bei. More Than 100 Studies From Pfizer's Extensive Oncology Portfolio to Be Presented at ASCO 2006 NEW YORK, June 2 -- Pfizer Inc said today it will present important data on cancer therapies and report progress across its oncology pipeline at the 2006 American Society for Clinical Oncology (ASCO) meeting in Atlanta, Georgia. More than 100 studies will be presented on Pfizer medicines, with new findings in breast, kidney, colorectal, gastrointestinal stromal tumor (GIST), lung, thyroid, melanoma, ovarian, and neuroendocrine cancer research. Following are key abstracts: PRODUCT TIME DATA SUTENT(R) June 3 SUTENT phase III results in (sunitinib malate) 4:45pm - gastrointestinal stromal tumors 5:00pm SUTENT(R) June 4 SUTENT phase II results in lung (sunitinib malate) 8:35am - cancer 8:50am SUTENT(R) June 4 phase III results of SUTENT (sunitinib malate) 3:10pm - versus interferon-alpha as a 3:25pm first-line systemic therapy for patients with advanced kidney cancer AROMASIN(R) June 5 Five year analysis of survival (exemestane tablets) 11:30am - data 11:45am CAMPTOSAR(R) June 5 CAMPTOSAR as a first-line (irinotecan HCl 3:30pm - treatment for colorectal cancer injection) 3:45pm "The breadth and depth of data presentations at ASCO will underscore the innovation behind Pfizer's oncology portfolio and our commitment to meeting critical patient and physician needs," said Dr. John LaMattina, president of Pfizer Global Research and Development. "Our team of scientists is working hard to transform cancer into a disease patients live with instead of die from." On Sunday, June 4, Pfizer will host a press briefing that will present new medical information on Pfizer cancer medicines and provide an overview on the company's broad oncology pipeline. The briefing will be held at the Westin Peachtree Plaza in Atlanta, Georgia, from 6:00 to 7:30 p.m. SOURCE Pfizer Inc -0- 06/02/2006 /CONTACT: Betsy Raymond, +1-212-733-6572, or cell, +1-860-501-3247 / /Company News On-Call: Pfizer's press releases are available through PR Newswire's Company News On-Call service on PRN's Web Site. Visit http://www.prnewswire.com/comp/688250.html/ /Photo: A free corporate logo to accompany this story is available immediately via Wieck Photo Database to any media with telephoto receiver or electronic darkroom, PC or Macintosh, that can accept overhead transmissions. To retrieve a logo, please call 972-392-0888./ /Web site: http://www.pfizer.com / (PFE) ENDPFIZER INC |
|
| aus der Diskussion: | Pfizer-Pharmawert total unterbewertet! 50% möglich! |
| Autor (Datum des Eintrages): | wellen (02.06.06 13:56:03) |
| Beitrag: | 19 von 2,450 (ID:21923129) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |